After the ebola outbreak in 2014, there has been lot of research for the development of a vaccine to prevent the disease. An Ebola virus disease (EVD) vaccine, developed in Canada, was well-tolerated with no safety concerns in the phase 1 randomized controlled trial. High antibodies were present in participants 6 months after immunization.